Previous clinical vaccination trials of BCR-ABL peptides demonstrated that certain amino-acid sequences crossing the p210 breakpoint were immunogenic in patients with chronic myeloid leukemia (CML), with 60-80% of patient's T cells responding to the vaccinating peptides. [1] [2] [3] [4] Antileukemic effects were suggested in two of these trials. 3, 4 Both trials involved patients with the b3a2 breakpoint. Native peptides from either b3a2 or b2a2 breakpoints demonstrating strong binding to human leukocyte antigen (HLA)-A0201 have not been identified, and CD8 responses to HLA-A0201-restricted peptides have also not been observed in vaccinated patients. We hypothesized that specific CD8 responses could be generated to class I HLA-A0201 peptides by rendering them more immunogenic through selective mutations in their HLA-binding sequences 5 and preclinical data have documented the immunogenicity of these sequences to human CD8 T cells. We therefore initiated a clinical trial administering synthetic analog peptide vaccines for either b3a2 or b2a2 breakpoints to CML patients. Eligible patients had obtained either a major or complete cytogenetic remission on a stable treatment regimen of imatinib therapy and were required to have molecular or cytogenetic measurable disease. Patients could not undergo other forms of therapy (exclusive of imatinib) during vaccination. Eleven vaccinations mixed in the immune adjuvant montanide were given: biweekly five doses, then monthly four doses, then at 9 and 12 months. Granulocyte-macrophage CSF (70 mg) was administered subcutaneously with each vaccine at the site of vaccination on days À2 and 0. Responses were evaluated at time 0, after five vaccinations and 2 weeks following the completion of therapy through delayed type hypersensitivity , CD4 T-cell proliferation, CD4 and CD8 T-cell interferon g ELISPOT, tetramer staining, 51 Cr release assay 1,2,5 as well as bone marrow cytogenetics and PCR (both quantitative and nested assays).
Patients with b3a2 breakpoint received a cocktail of five peptides (American Peptide Company, Sunnyvale, CA, USA) spanning the b3a2 fusion junction: two heteroclitic HLA-A0201-binding peptides, CML-A2-HC (KLLQRPVAV) and CML-HF(YLKALQRPV), and three native sequences: one HLA-A3-binding peptide, CML-A3 (KQSSKALQR) and one HLA-B8-binding peptide, CML-B8, (GFKQSSKAL) and one long class II peptide, B3A2 long (IVHSATGFKQSSKALQRPVASDFE). The additional b3a2 peptide sequences used for testing in vitro were: CML-A2-NC, (KALQRPVAS) and CML-A2-NF, (SSKALQRPV). Patients with b2a2 breakpoint received two peptides spanning the b2a2 fusion junction, which includes one class II peptide, Thirteen patients were treated during study (Table 1) . Vaccination was generally well tolerated with the most common toxicity being local induration or erythema at the site of inoculation. Eleven patients completed the planned 11 vaccinations. One patient was removed from the trial after nine vaccinations because of noncompliance, which rendered him inevaluable for response. Another patient with an extensive cardiac history experienced a significant adverse event by developing fever following the seventh vaccination, which in turn precipitated an anginal episode. The patient recovered without incident but was withdrawn from further therapy.
T-cell responses in peripheral blood from vaccinated patients were measured after stimulation of T cells twice in vitro. Patients with different HLA class I types were stimulated with their appropriate matched peptides, if available (for example, patients with HLA-A0201, -A0301, and -B8). Previous preclinical data had shown that there were no significant CD8 responses without prior in vitro stimulation, so those studies were not carried out as part of this study. Alternatively, no in vitro stimulation was performed prior to assessing CD4 responses. Patients without matching class I peptides in the vaccine were screened with the HLA-A0201 peptides as well to provide specificity data. A positive ELISPOT response was recorded if the vaccinating peptide elicited more than a twofold increase in spots over the controls and if there were more than 30 positive spots. Not all timepoints were available in all patients for technical reasons.
No immune responses were seen before vaccinations. Six of six patients with HLA-A0201 (three each with each breakpoint) and one patient with b3a2 and with HLA-A0205, which is closely related, responded to the A0201 analog peptide after five vaccinations. Four of the six patients with HLA-A0201 responded to a native peptide sequence after stimulation in vitro with the heteroclitic peptide or to native peptide as a stimulus (Figures 1a-d ). (Three of the patients did not have adequate Letters to the Editor samples at time 0 or after time 5 for comparison, so blood drawn at other time points was used).
One patient with HLA-A0301 did not have adequate cells to test. One of the two other HLA-A03 patients responded in ELISPOT assays to the A0301 native peptide after vaccination and remained positive when tested at the end of study (Figures  2a-b) . MHC tetramers were used to identify the responding cells as CD8-positive cells (data not shown for this patient). This patient also tested positively for CD8 cytotoxicity as measured by 51 Cr release assays using peptide pulsed, matched targets (Figure 2c ). No matching cell target was available to demonstrate killing without peptide pulsing. The one patient who was typed as b3a2 and HLA-B8 responded to the B8 native peptide after vaccination. (Figures 2d and e) As in earlier responses, MHC tetramers identified the CD8-positive cells (data not shown for this patient). CD8 responses to the HLA-A0201 peptides were negative in the three patients without HLA-A0201, -A0301 or -B8.
Four previous trials and several in vitro studies had demonstrated that normal donors and patients with CML were generally capable of making a CD4-immune response to long peptides crossing the BCR-ABL breakpoints. [1] [2] [3] [4] 6 In these trials, CD4 responses to the vaccinating peptides, as measured by delayed type hypersensitivity, ELISPOT or proliferation, ranged from 70 to 90% of patients. We confirmed this observation again in this trial using delayed type hypersensitivity and CD4 T-cell proliferation. 1,2 Nine of 13 patients reacted with the vaccinating long peptide after five vaccinations. Two of these patients had weak reactions prior to vaccination (5 and 10 mm). Eight of 13 patients reacted positively (nonanergic) to the anergy test. HLA-DRB1 types in responding patients (HLA-DR3, HLA-DR4, HLA-DR7, HLA-DR8, HLA-DR10, HLA-DR11, HLA-DR12, HLA-DR13 and HLA-DR15) and overlapped with HLA-DRB1 types in non-responding patients (HLA-DR1, HLA-DR7, HLA-DR8, HLA-DR15 and HLA-DR16). No correlations between HLA-DR type, delayed type hypersensitivity, anergy screen or breakpoint were apparent.
CD4 proliferation was measured in fresh CD4 T cells, isolated from the peripheral blood and stimulated on day 0 with the vaccinating peptides, no peptides or control peptides. On day 5, T cells were incubated with tritiated thymidine for 20 h and the amount of incorporation was determined. A positive response was recorded if the vaccinating peptide elicited more than a twofold increase in counts over the controls. Eleven of 13 patients reacted positively after vaccination. One of 13 patients reacted positively before vaccination. HLA-DR B1 types in responding patients (HLA-DR1, HLA-DR3, HLA-DR4, HLA-DR7, HLA-DR8, HLA-DR11, HLA-DR12, HLA-DR13 and HLA-DR15) overlapped with HLA-DRB1 types in the nonresponding patients (HLA-DR1, HLA-DR11, HLA-DR13 and HLA-DR15). No correlations between HLA-DR type, proliferative response, anergy screen or breakpoints were noted.
We also assessed antileukemic activity of the vaccine. Three of the patients had low levels of BCR-ABL positivity as detected by fluorescence in situ hybridization (FISH) prior to the trial. Two of these patients converted to FISH negativity following week 10 of vaccination. One other transiently converted to FISH negativity following week 10, but became positive at the 9-month time point prior to the 10th vaccination. This patient, however, was removed from the study because of noncompliance with the full vaccine regimen. None of the other patients had evidence of cytogenetic relapse (as detected by either standard karyotyping or FISH during the study. Both intra-and inter-laboratory baseline sensitivity variability among the serial measurements of BCR-ABL transcript levels made observations on the effect of vaccine therapy on molecular levels of disease difficult to interpret. Therefore, no consistent trend in quantitative transcript levels were noted in the patients who had evidence of immunologic response. Furthermore, at the end of study, all patients remained positive for BCR-ABL transcript in either the blood or bone marrow as measured by nested PCR.
In summary, we tested the hypothesis that we could generate T-cell responses in patients with both major breakpoints of BCR-ABL and HLA-A02 type by using heteroclitic sequences based on weakly binding HLA-A0201 sequences. Among the seven patients with HLA-A02, specific and cross-reacting (heteroclitic) CD8 responses were seen in four patients, suggesting that the effort to stimulate rare T-cell precursors reactive with the native sequence was successful for this group of patients. A specific CD8-immune response was seen in patients with the other appropriate HLA types (B8 and A3) after five vaccinations. Despite the immune response demonstrable in vitro, no data are available in this trial to show that the T cells were capable of killing fresh CML cells nor any clear clinical responses that correlated with the immune responses were seen. In addition, although there were two patients who converted the FISH test for BCR-ABL from positive to negative in the bone marrow, we were unable to demonstrate clinical efficacy against minimal molecular disease underscoring the difficulty clinical laboratories have for reproducibly detecting low levels of transcripts. 7, 8 All patients remained nested-PCR positive at the end of the trial.
This trial suggests that although it is possible to immunize patients with CML against their own breakpoint peptides, there may be insufficient processing or presentation of the appropriate peptides on the cell surface of target CML cells or too weak a T-cell response to allow for clinically relevant activity, even in the setting of minimal disease. Indeed, only the A3 peptide has been demonstrated on the cell surface of CML cells by mass spectrometric methods. 9 Moreover, as there are an enlarging number of selective kinase inhibitors available for the treatment of CML, and the reduction in BCR-ABL transcripts as measured by reverse transcriptase PCR after treatment with these inhibitors for long periods is reaching the limits of reliability and sensitivity of quantitative measurements, the design of a trial that could definitively demonstrate the benefits of vaccination would likely require large number of patients, randomized groups and a survival endpoint.
